Literature DB >> 16476109

Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register.

M Ridderstråle1, S Gudbjörnsdottir, B Eliasson, P M Nilsson, J Cederholm.   

Abstract

OBJECTIVES: To compare obese with normal and overweight type 2 diabetic patients regarding body mass index (BMI) and cardiovascular risk factors, and to analyse changes in weight versus risk factors. DESIGN AND
SETTING: A cross-sectional study of 44 042 type 2 patients, and a 6-year prospective study of 4468 type 2 patients.
RESULTS: Obese patients (BMI > or = 30 kg m(-2)), 37% of all patients, had high frequencies of hypertension (88%), hyperlipidaemia (81%) and microalbuminuria (29%). Only 11% had blood pressure <130/80 mmHg. Their ratio of triglycerides to HDL cholesterol was considerably elevated, whilst the mean total and LDL cholesterol were similar as in normal weight subjects. Obese patients had elevated odds ratios for hypertension, hyperlipidaemia and microalbuminuria: 2.1, 1.8 and 1.4 in the cross-sectional study, similarly confirmed in the prospective 6-year study. BMI was an independent predictor of these risk factors (P < 0.001), although only slightly associated with HbA1c and not with total or LDL cholesterol. A change in BMI during the prospective study was related to a change in HbA1c in patients treated with diet and oral hypoglycaemic agents (OHAs) but not with insulin. In all patients, an increase in BMI was related to the development of hypertension, and a change in BMI to change in blood pressure, also mostly confirmed when treated with diet, OHAs or insulin.
CONCLUSIONS: The high frequencies of risk factors in obese type 2 patients implies an increased risk of cardiovascular disease and the need for therapeutic measures. The paradox that hypoglycaemic treatment accompanied by weight gain may increase cardiovascular risk factors seems to be verified here concerning hypertension but not concerning microalbuminuria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16476109     DOI: 10.1111/j.1365-2796.2006.01617.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  26 in total

Review 1.  Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.

Authors:  Israel Hartman
Journal:  Clin Med Res       Date:  2008-09-18

2.  Does chronic kidney disease modify the association between body mass index and cardiovascular disease risk factors.

Authors:  Nisha Bansal; Eric Vittinghoff; Laura Plantinga; Chi-Yuan Hsu
Journal:  J Nephrol       Date:  2012 May-Jun       Impact factor: 3.902

3.  Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index.

Authors:  Katarina Raslová; Soren Can Tamer; Per Clauson; Diane Karl
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 4.  Obesity and cardiovascular disease in women.

Authors:  Camila Manrique-Acevedo; Bhavana Chinnakotla; Jaume Padilla; Luis A Martinez-Lemus; David Gozal
Journal:  Int J Obes (Lond)       Date:  2020-02-17       Impact factor: 5.095

5.  Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients.

Authors:  K Eeg-Olofsson; J Cederholm; P M Nilsson; B Zethelius; L Nunez; S Gudbjörnsdóttir; B Eliasson
Journal:  Diabetologia       Date:  2008-11-05       Impact factor: 10.122

6.  Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.

Authors:  Edward S Horton; Cheryl Silberman; Keith L Davis; Rachele Berria
Journal:  Diabetes Care       Date:  2010-05-11       Impact factor: 19.112

Review 7.  Antidiabetic medications and weight gain: implications for the practicing physician.

Authors:  Samy I McFarlane
Journal:  Curr Diab Rep       Date:  2009-06       Impact factor: 4.810

Review 8.  Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus.

Authors:  Kjeld Hermansen; Lene S Mortensen
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

9.  Factors of cardiovascular risk in patients with type 2 diabetes and incipient nephropathy.

Authors:  E Nelaj; M Gjata; I Lilaj; G Burazeri; E Sadiku; L Collaku; O Bare; M Tase
Journal:  Hippokratia       Date:  2008       Impact factor: 0.471

10.  Predicting Changes in Cardiovascular Risk Factors in Type 2 Diabetes in the Post-UKPDS Era: Longitudinal Analysis of the Swedish National Diabetes Register.

Authors:  Aliasghar Ahmad Kiadaliri; Philip M Clarke; Ulf-G Gerdtham; Peter Nilsson; Björn Eliasson; Soffia Gudbjörnsdottir; Katarina Steen Carlsson
Journal:  J Diabetes Res       Date:  2013-02-28       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.